John F Marshall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2631034/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Synthesis and Systematic Study on the Effect of Different PEG Units on Stability of PEGylated, Integrin-αvβ6-Specific A20FMDV2 Analogues in Rat Serum and Human Plasma. Molecules, 2022, 27, 4331.	1.7	Ο
2	CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1538-1552.	3.2	39
3	Harnessing the power of foot-and-mouth-disease virus for targeting integrin alpha-v beta-6 for the therapy of cancer. Expert Opinion on Drug Discovery, 2021, 16, 737-744.	2.5	10
4	The ITGB6 gene: its role in experimental and clinical biology. Gene: X, 2020, 5, 100023.	2.3	29
5	Epidermolysis bullosa. Nature Reviews Disease Primers, 2020, 6, 78.	18.1	182
6	Integrin αvl²6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. Theranostics, 2020, 10, 2930-2942.	4.6	28
7	The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Journal of Pathology, 2019, 249, 332-342.	2.1	66
8	Integrin-Mediated TGFÎ ² Activation Modulates the Tumour Microenvironment. Cancers, 2019, 11, 1221.	1.7	62
9	Probing the nanoscale organisation and multivalency of cell surface receptors: DNA origami nanoarrays for cellular studies with single-molecule control. Faraday Discussions, 2019, 219, 203-219.	1.6	36
10	DNA Origami Nanoarrays for Multivalent Investigations of Cancer Cell Spreading with Nanoscale Spatial Resolution and Single-Molecule Control. ACS Nano, 2019, 13, 728-736.	7.3	60
11	PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer. Cell Reports, 2018, 22, 2469-2481.	2.9	34
12	The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells. Molecular Cancer Therapeutics, 2018, 17, 575-587.	1.9	41
13	Correlative 3D Structured Illumination Microscopy and Single-Molecule Localization Microscopy for Imaging Cancer Invasion. Methods in Molecular Biology, 2018, 1764, 253-265.	0.4	3
14	Targeting CDH17 in Cancer: When Blocking the Ligand Beats Blocking the Receptor?. Clinical Cancer Research, 2018, 24, 253-255.	3.2	5
15	Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells. Molecular Therapy, 2017, 25, 259-273.	3.7	61
16	Investigating in vitro and in vivo $\hat{I}\pm v \hat{I}^2 6$ integrin receptor-targeting liposomal alendronate for combinatory $\hat{I}^3 \hat{I}$ T cell immunotherapy. Journal of Controlled Release, 2017, 256, 141-152.	4.8	25
17	Structure-activity relationship study of the tumour-targeting peptide A20FMDV2 via modification of Lys16, Leu13, and N- and/or C-terminal functionality. European Journal of Medicinal Chemistry, 2017, 136, 154-164.	2.6	11
18	Proâ€migratory and TGFâ€Î²â€activating functions of αvβ6 integrin in pancreatic cancer are differentially regulated via an Eps8â€dependent GTPase switch. Journal of Pathology, 2017, 243, 37-50.	2.1	27

JOHN F MARSHALL

#	Article	IF	CITATIONS
19	Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function. Breast Cancer Research, 2017, 19, 33.	2.2	29
20	Integrins as Therapeutic Targets: Successes and Cancers. Cancers, 2017, 9, 110.	1.7	177
21	Eighteen-year follow-up of hyperopic photorefractive keratectomy. Journal of Cataract and Refractive Surgery, 2016, 42, 258-266.	0.7	18
22	Sixteen-year follow-up of hyperopic laser in situ keratomileusis. Journal of Cataract and Refractive Surgery, 2016, 42, 717-724.	0.7	24
23	The role of integrins in TGF \hat{I}^2 activation in the tumour stroma. Cell and Tissue Research, 2016, 365, 657-673.	1.5	87
24	αvβ6 Expression in Myoepithelial Cells: A Novel Marker for Predicting DCIS Progression with Therapeutic Potential. Cancer Research, 2014, 74, 5942-5947.	0.4	32
25	Therapeutic Targeting of Integrin αvβ6 in Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	132
26	A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Medicine, 2014, 6, 105.	3.6	106
27	Rigidity sensing and adaptation through regulation of integrin types. Nature Materials, 2014, 13, 631-637.	13.3	304
28	Suppression of Hedgehog signalling promotes proâ€ŧumourigenic integrin expression and function. Journal of Pathology, 2014, 233, 196-208.	2.1	7
29	Preclinical SPECT/CT Imaging of $\hat{1}\pm v \hat{1}^2 6$ Integrins for Molecular Stratification of Idiopathic Pulmonary Fibrosis. Journal of Nuclear Medicine, 2013, 54, 2146-2152.	2.8	84
30	Structural Guided Scaffold Phage Display Libraries as a Source of Bio-Therapeutics. PLoS ONE, 2013, 8, e70452.	1.1	10
31	Generation and Characterization of a Diabody Targeting the $\hat{1}\pm v \hat{1}^2 6$ Integrin. PLoS ONE, 2013, 8, e73260.	1.1	11
32	S100P-Binding Protein, S100PBP, Mediates Adhesion through Regulation of Cathepsin Z in Pancreatic Cancer Cells. American Journal of Pathology, 2012, 180, 1485-1494.	1.9	34
33	NMR relaxation and structural elucidation of peptides in the presence and absence of trifluoroethanol illuminates the critical molecular nature of integrin αvβ6 ligand specificity. RSC Advances, 2012, 2, 11019.	1.7	9
34	The role of α9β1 integrin in modulating epithelial cell behaviour. Journal of Oral Pathology and Medicine, 2011, 40, 755-761.	1.4	8
35	Transwell® Invasion Assays. Methods in Molecular Biology, 2011, 769, 97-110.	0.4	170
36	Betelâ€derived alkaloid upâ€regulates keratinocyte alphavbeta6 integrin expression and promotes oral submucous fibrosis. Journal of Pathology, 2011, 223, 366-377.	2.1	91

JOHN F MARSHALL

#	Article	IF	CITATIONS
37	Stromal features are predictive of disease mortality in oral cancer patients. Journal of Pathology, 2011, 223, 470-481.	2.1	260
38	Pancreatic cancer organotypic cultures. Journal of Biotechnology, 2010, 148, 16-23.	1.9	44
39	Highâ€resolution <i>in vivo</i> imaging of breast cancer by targeting the proâ€invasive integrin αvβ6. Journal of Pathology, 2010, 222, 52-63.	2.1	56
40	Inflammation-dependent α5β1 (very late antigen-5) expression on leukocytes reveals a functional role for this integrin in acute peritonitis. Journal of Leukocyte Biology, 2010, 87, 877-884.	1.5	11
41	Two-dimensional heteronuclear saturation transfer difference NMR reveals detailed integrin αvβ6 protein–peptide interactions. Chemical Communications, 2010, 46, 7533.	2.2	20
42	Engineering a Single-Chain Fv Antibody to αvβ6 Integrin Using the Specificity-Determining Loop of a Foot-and-Mouth Disease Virus. Journal of Molecular Biology, 2008, 382, 385-401.	2.0	30
43	Foot-and-Mouth Disease Virus Forms a Highly Stable, EDTA-Resistant Complex with Its Principal Receptor, Integrin αvβ6: Implications for Infectiousness. Journal of Virology, 2008, 82, 1537-1546.	1.5	68
44	New therapeutic avenues for age-related macular degeneration: targeting Bruch's membrane. Expert Review of Ophthalmology, 2008, 3, 353-356.	0.3	0
45	αvβ6 Integrin Promotes the Invasion of Morphoeic Basal Cell Carcinoma through Stromal Modulation. Cancer Research, 2008, 68, 3295-3303.	0.4	73
46	Use of a Peptide Derived from Foot-and-Mouth Disease Virus for the Noninvasive Imaging of Human Cancer: Generation and Evaluation of 4-[18F]Fluorobenzoyl A20FMDV2 for <i>In vivo</i> Imaging of Integrin αvβ6 Expression with Positron Emission Tomography. Cancer Research, 2007, 67, 7833-7840.	0.4	119
47	Structure-Function Analysis of Arg-Gly-Asp Helix Motifs in αvβ6 Integrin Ligands. Journal of Biological Chemistry, 2007, 282, 9657-9665.	1.6	82
48	HS1-Associated Protein X-1 Regulates Carcinoma Cell Migration and Invasion via Clathrin-Mediated Endocytosis of Integrin αvβ6. Cancer Research, 2007, 67, 5275-5284.	0.4	127
49	Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nature Cell Biology, 2007, 9, 1392-1400.	4.6	1,281
50	Tumor Cell Migration in Three Dimensions. Methods in Enzymology, 2006, 406, 625-643.	0.4	60
51	Cyclooxygenase-2 Inhibition Suppresses αvβ6 Integrin–Dependent Oral Squamous Carcinoma Invasion. Cancer Research, 2006, 66, 10833-10842.	0.4	59
52	Clinical results of the blue-light filtering AcrySof Natural foldable acrylic intraocular lens. Journal of Cataract and Refractive Surgery, 2005, 31, 2319-2323.	0.7	57
53	TNF-α regulates epithelial expression of MMP-9 and integrin αvβ6 during tumour promotion. A role for TNF-α in keratinocyte migration?. Oncogene, 2004, 23, 6954-6966.	2.6	83
54	Modulation of the urokinase-type plasminogen activator receptor by the β6 integrin subunit. Biochemical and Biophysical Research Communications, 2004, 317, 92-99.	1.0	17

JOHN F MARSHALL

#	Article	IF	CITATIONS
55	The minimum stimulus energy required to produce a cooling sensation in the human cornea. Ophthalmic and Physiological Optics, 2001, 21, 407-410.	1.0	22
56	αvβ6 Integrin Upregulates Matrix Metalloproteinase 9 and Promotes Migration of Normal Oral Keratinocytes. Journal of Investigative Dermatology, 2001, 116, 898-904.	0.3	87
57	Expression of the αvβ6 Integrin Promotes Migration and Invasion in Squamous Carcinoma Cells. Journal of Investigative Dermatology, 2001, 117, 67-73.	0.3	114
58	Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with Ad5 fibre binding is mediated by ?v?1 integrin and can be modulated by changes in ?1 integrin function. Journal of Gene Medicine, 2001, 3, 550-559.	1.4	50
59	αvβ6integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. International Journal of Cancer, 2001, 92, 641-650.	2.3	140
60	Melanocortins are comparable to corticosteroids as inhibitors of traumatic ocular inflammation in rabbits. , 2001, 239, 840-844.		10
61	In vivo therapy of malignant melanoma by means of antagonists of αv integrins. International Journal of Cancer, 2000, 87, 716-723.	2.3	167
62	In vivo therapy of malignant melanoma by means of antagonists of αv integrins. International Journal of Cancer, 2000, 87, 716-723.	2.3	6
63	Morphometric study of the displacement of retinal ganglion cells subserving cones within the human fovea. Graefe's Archive for Clinical and Experimental Ophthalmology, 1999, 237, 1014-1023.	1.0	69
64	Reliability of the Non-Contact Corneal Aesthesiometer and its comparison with the Cochet-Bonnet aesthesiometer. Ophthalmic and Physiological Optics, 1998, 18, 532-539.	1.0	59
65	Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. International Journal of Cancer, 1997, 71, 267-274.	2.3	175
66	Activation status and function of the VLA-4 ($\hat{l}\pm4\hat{l}^21$) integrin expressed on human melanoma cell lines. , 1997, 73, 264-270.		14
67	Generation of an antiâ€ŧumour immune response in a nonâ€ŧmmunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1â€ŧike profile of intratumoural cytokine expression. International Journal of Cancer, 1997, 71, 267-274.	2.3	3
68	Angiographic abnormalities of experimental autoimmune uveoretinitis. Current Eye Research, 1996, 15, 1149-1155.	0.7	12
69	The role of αv-integrins in tumour progression and metastasis. Seminars in Cancer Biology, 1996, 7, 129-138.	4.3	91
70	A new non-contact corneal aesthesiometer (NCCA). Ophthalmic and Physiological Optics, 1996, 16, 101-107.	1.0	64
71	Corneal sensitivity recovery after photorefractive keratectomy (PRK). Ophthalmic and Physiological Optics, 1996, 16, 250-250.	1.0	3
72	Decreasing hydraulic conductivity of Bruch's membrane: Relevance to photoreceptor survival and lipofuscinoses. American Journal of Medical Genetics Part A, 1995, 57, 235-237.	2.4	43

#	Article	IF	CITATIONS
73	Disturbances in night vision after excimer laser photorefractive keratectomy. Eye, 1994, 8, 46-51.	1.1	74